Drug Profile
Research programme: brain cancer therapeutics - CombinatoRx
Latest Information Update: 22 Sep 2010
Price :
$50
*
At a glance
- Originator CombinatoRx
- Developer Zalicus
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 01 Oct 2004 Preclinical trials in Glioblastoma in USA (unspecified route)